The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Rowe, Warren; Cheng, Xiaoqian; Ly, Lawan; Zhuang, Taisen; Basadonna, Giacomo; Trink, Barry; Keidar, Michael; Canady, Jerome

doi:10.3390/plasma1010016

Cited by 19 publications

(23 citation statements)

References 44 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further illustrate the correspondence between cell viability and CAP power and treatment time, we calculate the energy delivered by the system; E. The close correlation between energy consumption and reduction in viability may be important for comparing results between different CAP devices. Difference cell types may also respond differently to CAP treatment, therefore more studies have been performed to confirm the efficacy of the CAP system on other solid tumor cancer cell lines [31] as well as the safety of the unit on normal tissue [32]. Future animal studies are needed to determine the optimal dosage for cancer elimination while remaining safe for normal tissue.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results

Cheng¹,

Rowe²,

Ly³

et al. 2018

Plasma

Self Cite

View full text Add to dashboard Cite

Triple-negative breast cancer is a phenotype of breast cancer where the expression level of estrogen, progesterone and human epidermal growth factor receptor 2 (HER2) receptors are low or absent. It is more frequently diagnosed in younger and premenopausal women, among which African and Hispanic have a higher rate. Cold atmospheric plasma has revealed its promising ant-cancer capacity over the past two decades. In this study, we report the first cold plasma jet delivered by the Canady Cold Plasma Conversion Unit and characterization of its electric and thermal parameters. The unit effectively reduced the viability of triple-negative breast cancer up to 80% without thermal damage, providing a starting point for future clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results

Cheng¹,

Rowe²,

Ly³

et al. 2018

Plasma

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have also demonstrated that the CAP jet significantly reduced cell viability in a dose-dependent manner in various cell lines such as 769-P (renal adenocarcinoma), HCT-116 (colorectal carcinoma), SK-OV-3 (ovarian adenocarcinoma), BxPC-3 (pancreatic adenocarcinoma), OE33 (oesophageal adenocarcinoma), and MDA-MB-231 (breast adenocarcinoma) [17,18]. With various CAP dosages, an 80-99% reduction in viability of these cancer cells lines was achieved 48 h after treatment [17]. However, the safety of this new device must be taken into consideration.…”

Section: Introductionmentioning

confidence: 81%

“…In our recent study, we have shown that the spectrum of CAP, generated by the USMI Cold Plasma Conversion Unit and Canady Helios Cold Plasma Scalpel, mainly consists of N 2 , N 2 + , He, and O [17].…”

Section: Introductionmentioning

confidence: 99%

A New Cold Plasma Jet: Performance Evaluation of Cold Plasma, Hybrid Plasma and Argon Plasma Coagulation

Ly¹,

Jones²,

Shashurin

et al. 2018

Plasma

Self Cite

View full text Add to dashboard Cite

The use of plasma energy has expanded in surgery and medicine. Tumor resection in surgery and endoscopy has incorporated the use of a plasma scalpel or catheter for over four decades. A new plasma energy has expanded the tools in surgery: Cold Atmospheric Plasma (CAP). A cold plasma generator and handpiece are required to deliver the CAP energy. The authors evaluated a new Cold Plasma Jet System. The Cold Plasma Jet System consists of a USMI Cold Plasma Conversion Unit, Canady Helios Cold Plasma® Scalpel, and the Canady Plasma® Scalpel in Hybrid and Argon Plasma Coagulation (APC) modes. This plasma surgical system is designed to remove the target tumor with minimal blood loss and subsequently spray the local area with cold plasma. In this study, various operational parameters of the Canady Plasma® Scalpels were tested on ex vivo normal porcine liver tissue. These conditions included various gas flow rates (1.0, 3.0, 5.0 L/min), powers (20, 40, 60 P), and treatment durations (30, 60, 90, 120 s) with argon and helium gases. Plasma length, tissue temperature changes, and depth and eschar injury magnitude measurements resulting from treatment were taken into consideration in the comparison of the scalpels. The authors report that a new cold plasma jet technology does not produce any thermal damage to normal tissue.

show abstract

“…Cold atmospheric plasma (CAP) has been extensively studied in various biomedical elds. It is a novel approach to targeted cancer treatment and has demonstrated its anti-cancer effects in vitro [16][17][18][19] . The detailed mechanism have not been fully elucidated, however studies have established that CAP selectively induces apoptosis and DNA damage in tumor cells [20][21][22] .…”

Section: Introductionmentioning

confidence: 99%

The Synergistic Effect of Canady Helios Cold Atmospheric Plasma and A Folfirinox Regimen for The Treatment of Cholangiocarcinoma In Vitro

Jones¹,

Cheng²,

Murthy³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a rare biliary tract cancer with a low five-year survival rate and high recurrence rate after surgical resection. Currently treatment approaches include systemic chemotherapeutics such as FOLFIRINOX, a chemotherapy regimen is a possible treatment for severe CCA cases. A limitation of this chemotherapy regimen is its toxicity to patients and adverse events. There exists a need for therapies to alleviate the toxicity of a FOLFIRINOX regimen while enhancing or not altering its anticancer properties. Cold Atmospheric plasma (CAP) is a technology with a promising future as a selective cancer treatment. It is critical to know the potential interactions between CAP and adjuvant chemotherapeutics. In this study the aim is to characterize the efficacy of FOLFIRINOX and CAP in combination to understand potential synergetic effect on CCA cells. FOLFIRINOX treatment alone at the highest dose tested (53.8 nM fluorouracil, 13.1 nM Leucovorin, 5.1 nM Irinotecan, and 3.7 nM Oxaliplatin) reduced CCA cell viability to below 20% while CAP treatment alone for 7 min reduced viability to 3% (p < 0.05). An analysis of cell viability, proliferation, and cell cycle demonstrated that CAP in combination with FOLFIRINOX is more effective than either treatment alone at a lower FOLFIRINOX dose of 6.73 nM fluorouracil, 1.71 nM leucovorin, 0.63 nM irinotecan, and 0.47 nM oxaliplatin and a shorter CAP treatment of 1, 3, or 5 minutes. In conclusion, CAP has the potential to reduce the toxicity burden of FOLFIRINOX and warrants further investigation as an adjuvant therapy.

show abstract

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Cited by 19 publications

References 44 publications

Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results

Treatment of Triple-Negative Breast Cancer Cells with the Canady Cold Plasma Conversion System: Preliminary Results

A New Cold Plasma Jet: Performance Evaluation of Cold Plasma, Hybrid Plasma and Argon Plasma Coagulation

The Synergistic Effect of Canady Helios Cold Atmospheric Plasma and A Folfirinox Regimen for The Treatment of Cholangiocarcinoma In Vitro

Contact Info

Product

Resources

About